

Claudio Jommi is Professor of Management at the Department of Pharmaceutical Sciences, Università del Piemonte Orientale and Member of the Programme Board and Scientific Committee of the Master of Discipline Regolatorie e Market Access in Ambito Farmaceutico e Biotecnologico. He was Professor of Practice of Health Policy at SDA Bocconi School of Management, where he held the position of Director of the Master of International Health Care Management Economics and Policy (Mihmep), and Director of the Health Policy Area and Scientific Coordinator of the Pharmaceutical Observatory at Cergas (Centre for Research on Health and Social Care Management). He was the President of the Italian Health Economics Association. He is the Editor in Chief of GRHTA (Global and Regional Health Technology Assessment), His research activity is focused on Pharmaceutical Economics, Policy and Management, Health Technology Assessment and Market Access for Medicines. He has had his work published in many international and national journals, including Applied Health Economics and Policy, BMC Health Services Research, BMJ Open, Drug Design Development and Therapy, Frontiers in Pharmacology, European Journal of Health Economics, Health Policy, International Journal of Health Planning and Management, Journal of Medical Marketing, Pharmacoeconomics and Pharmacoeconomics Open, PLOS and PLOS Neglected Diseases, Public Money and Management, Social Science and Medicine, Value in Health.

Main publications

Papers

- Meregaglia M, Malandrini F, Finch AP, Ciani O, **Jommi C**. EQ-5D-5L Population Norms for Italy. Appl Health Econ Health Policy. 2023 Mar;21(2):289-303.
- **Jommi C**, Galeone C. The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency. Pharmacoecon Open. 2023 Feb 10.
- Bertolani A, Ravasio R, Raimondo P, **Jommi C**. Il costo a carico dei pazienti del percorso per eleggibilità ai farmaci PCSK9 e follow-up di un anno: i risultati dello Studio PRIOR. Glob Reg Health Technol Assess. 2022 Jul 18;9:73-81.
- **Jommi C**, Bramanti S, Pani M, Ghirardini A, Santoro A. CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions. Front Pharmacol. 2022 Jun 23;13:915342.
- Whittal A, **Jommi C**, De Pouvourville G, Taylor D, Annemans L, Schoonaert L, Vermeersch S, Hutchings A, Patris J. Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. Int J Technol Assess Health Care 2022;38(1):e23.
- Finch AP, Meregaglia M, Ciani O, Roudijk B, **Jommi C**. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med 2022;292:114519
- **Jommi C**, Pantellini F, Stagi L, Verykiou M, Cavazza M. The economic impact of compassionate use of medicines. BMC Health Services Research 2021;21:1303
- **Jommi C**, Listorti E, Villa F, Ghislandi S, Genazzani A, Cangini A, Trotta F. Variables affecting pricing of orphan drugs: the Italian case. Orphanet J Rare Dis 2021;16(1):439

- Riva S, Efficace F, Di Maio M, Bryce J, Del Campo L, De Lorenzo F, Frontini L, Giannarelli D, Gitto L, Iannelli E, **Jommi C**, Montesarchio V, Tracò F, Vaccaro CM, Arenare L, Canzanella G, Gimigliano A, Romano F, Savio A, Sparavigna L, Piccirillo MC, Guizzaro L, Gallo C, Perrone F. A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. *Support Care Cancer* 2021;29(6):3219-3233
- Ronco V, Dilecce M, Lanati E, Canonico PL, **Jommi C**. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? *J Pharm Policy Pract* 2021;14(1):30
- Riva S, Arenare L, Di Maio M, Efficace F, Montesarchio V, Frontini L, Giannarelli D, Bryce J, Del Campo L, De Lorenzo F, Iannelli E, Tracò F, Gitto L, **Jommi C**, Vaccaro CM, Barberio D, Cinieri S, Porta C, Del Mastro L, Zagonel V, Cogoni AA, Bordonaro R, Gimigliano A, Piccirillo MC, Guizzaro L, Gallo C, Perrone F. Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. *BMJ Open* 2021;11(10):e049128
- Rognoni C, Bertolani A, **Jommi C**. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. *Clin Drug Investig* 2021;41(4):303-319
- Pruneri G, De Braud F, Sapino A, Aglietta M, Vecchione A, Giusti R, Marchiò C, Scarpino S, Baggi A, Bonetti G, Franzini Jm, Volpe M, **Jommi C**. Next-Generation Sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach? *Pharmacoeconomics Open* 2021;5(2):285-298
- Galeone C, Bruzzi P, **Jommi C**. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system. *BMJ Open* 2021;11,1:e041259
- Bertolani A, **Jommi C**. Local policies on biosimilars: are they designed to optimize use of liberated resources? *Generics and Biosimilars Initiative Journal (GaBI Journal)* 2020;9(4):163-70
- Armeni P, Borsoi L, Fornaro G, **Jommi C**, Grossi F, Costa F. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service. *Clin Ther* 2020;42(5):830-847
- Armeni P, Borsoi L, Fornaro G, **Jommi C**, Colombo N, Costa F. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. *Clin Ther* 2020;42(7):1192-1209
- **Jommi C**, Armeni P, Costa F, Bertolani A, Otto M. Implementation of Value-based Pricing for Medicines. *Clin Ther* 2020;42(1):15-24
- Armeni P, Borsoi L, Fornaro G, **Jommi C**, Grossi F, Costa F. Cost-effectiveness and Net Monetary Benefit of durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service. *Clin Ther* 2020 27:S0149-2918(20):30177-6
- Cavazza M, Banks H, Muscaritoli M, Rondanelli MA, Zandonà E, **Jommi C**. Patient access to oral nutritional supplements: which policies count? *Nutrition* 2020;69:110560.

- Riva S, Bryce J, De Lorenzo F, Del Campo L, Di Maio M, Efficace F, Frontini F, Giannarelli D, Gitto L, Iannelli E, **Jommi C**, Montesarchio V, Traclò V, Vaccaro CM, Gallo C, Perrone F. Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. *BMJ Open*. 2019; 9(9): e031485
- **Jommi C**, Cipriani F, Fanelli F, Pedone MP, Canonica W. The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service. *GRHTA (Global & Regional Health Technology Assessment)*. 2020; 7(1):33-9
- Villa F, Tutone M, Altamura G, Antignani S, Cangini A, Fortino I, Melazzini M, Trotta F, Tafuri G, **Jommi C**. Determinants of price negotiations for new drugs. The experience of the Italian Medicine Agency. *Health Policy* 2019 123(6):595-600
- Jommi C, Cavazza M. Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals. *GRHTA (Global & Regional Health Technology Assessment)* 2019:1-12
- Rognoni C, Bertolani A, **Jommi C**. Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives *GRHTA (Global & Regional Health Technology Assessment)* 2018:1-11
- Otto MH, Pillarella C, **Jommi C**. The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy. *Front Pharmacol* 2018; 9: 1069
- Federici C, Cavazza M, Costa F, **Jommi C**. Health care costs of influenza-related episodes in high income countries: A systematic review. *PLoS One* 2018;13(9):e0202787
- **Jommi C**, Bertolani A. Patients' Associations and HTA for medicines: actual and future role in Italy, *GRHTA (Global & Regional Health Technology Assessment)* 2018:1-11
- Otto M, Patrizio A, **Jommi C**. Variations in non-prescription drug consumption and expenditure: determinants and policy implications. *Health Policy* 2018;122(6):614-620
- Espin J, Schlander M, Godman B, Anderson P, Mestre-Ferrandiz J, Borget I, Hutchings A, Flostrand S, Parnaby A, **Jommi C**. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. *Appl Health Econ Health Policy* 2018;16(6):803-817
- **Jommi C**, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, Cozzolino M, Costanzo AM, di Luzio Paparatti U, Concas G, Remuzzi G. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study *Pharmacoecon Open* 2018;2(4):459-467
- Callea G, Armeni P, Marsilio M, **Jommi C**, Tarricone R. The impact of HTA and procurement practices on the selection and prices of medical devices. *Soc Sci Med* 2017;174:89-95
- Lucioni C, **Jommi C**. Value of health technologies, HTA and decisions. *GRHTA (Global & Regional Health Technology Assessment)* 2017;4(1): e41-e43
- Nayroles G, Frybourg S, Gabriel S, Kornfeld Å, Antoñanzas-Villar F, Espín J, **Jommi C**, Martini N, de Pouvourville G, Tolley K, Wasem J, Toumi M. Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. *J Mark Access Health Policy* 2017;5(1):1298190
- Perrone F, **Jommi C**, Di Maio M, Gimigliano A, Gridelli C, Pignata S, Ciardiello F, Nuzzo F, de Matteis A, Del Mastro L, Bryce J, Daniele G, Morabito A, Piccirillo MC, Rocco G, Guizzaro L, Gallo C. The association of financial difficulties with clinical outcomes in cancer patients:

secondary analysis of 16 academic prospective clinical trials conducted in Italy. *Ann Oncol* 2016;27(12):2224-2229

- Sommariva S, Finch AP, **Jommi C**. The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians. *Multidiscip Respir Med* 2016 Jan;27:11:4
- Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, **Jommi C**, Kaitelidou D, Kawalec P, Keskimaki I, Kroneman M, Lopez Bastida J, Pita Barros P, Ramsberg J, Schneider P, Spillane S, Vogler S, Vuorenkoski L, Wallach Kildemoes H, Wouters O, Busse R. Pharmaceutical regulation in 15 European countries review. *Health Syst Transit* 2016;18(5):1-122
- Ciani O, Armeni P, Boscolo PR, Cavazza M, **Jommi C**, Tarricone R. De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making. *Health Policy and Technology* 2016;5(1):47-64
- Finch AP, Dritsaki M, **Jommi C**. Generic Preference Based Measures for Low Back Pain: Which of Them Should Be Used? *Spine* 2016;41(6):e364-74.
- Armeni P, **Jommi C**, Otto M. The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study. *Eur J Health Econ* 2016;17(8):963-977
- **Jommi C**. Innovation and drugs price and reimbursement: a comparison between Italy and the other major EU countries. *GRHTA (Global and Regional Health Technology Assessment)* 2015;2(3):117-162.
- Gehring M, **Jommi C**, Tarricone T, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). *Epidemiology, Biostatistics and Public Health* 2015;12(1):e10246-1/9
- Joppi R, Cinconze E, Demattè L, Guseo R, **Jommi C**, Mortarino C, Pase D, Poggiani C, Roggeri A, Roggeri D. A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results. *J Pharm Policy Pract* 2015; 8(Suppl 1): P9
- Ciani O, **Jommi C**. The role of health technology assessment bodies in shaping drug development. *Drug Des Devel Ther* 2014;8:2273-81.
- Di Procolo P, **Jommi C**. Current pipelines for neglected diseases. *PLoS Negl Trop Dis*. 2014;8(9):e3092
- Cargin S, **Jommi C**, Canonico PL, Genazzani AA, Terrazzino S. Diagnostic accuracy of HLA-B*5701 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. *Pharmacogenomics* 2014;15(7):963-76
- Callea G, Armeni P, Tarricone R, Cavazza M, **Jommi C**. The Determinants of Uptake and Diffusion of Innovative Health Technologies. An Empirical Analysis. *Value Health* 2014;17(7):A501
- **Jommi C**, Costa E, Michelon A, et al. Multi-tier drugs assessment in a decentralised health care system. The Italian case-study, *Health Policy* 2013; 112(3):241-247
- Ghislandi S, Armeni P, **Jommi C**. The impact of generic reference pricing in Italy, a decade on. *Eur J Health Econ* 2013;4(6): 959-69

- Costa E, Biasi V, Concia E, **Jommi C**. Lattuada E, Manfre S, Venturini F, Lanzafame M. Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital. *Infez Med* 2014;22(2):118-23
- Toumi M, Zard J, Duvillard R, **Jommi C**. Innovative medicines and market access agreements, *Ann Pharm Fr* 2013;71(5):302-25
- Compagni A, Cavalli L, **Jommi C**. Pharmaceutical companies and Italian Regional Governments: Managing relationships in an increasing institutional complexity. *Health Policy* 2008;87(3):333-41
- Fattore G, **Jommi C**. The last decade of Italian Pharmaceutical Policy: Instability or Consolidation? *Pharmacoeconomics*. 2008;26(1):5-15
- **Jommi C**, Paruzzolo S. Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case study 2007;81(1):117-30.
- Anessi Pessina E, Cantù E, **Jommi C**. Phasing out market mechanisms in the Italian National Health Service, *Public Money & Management* 2004;5:309-316.
- **Jommi C**, Cantù E, Anessi Pessina E. New funding arrangements in the Italian National Health Service, *International Journal of Health Planning and Management* 2001;6:347-368.

Books and chapters in books

- **Jommi C** (2018). Managed Entry Agreements and High Cost Medicines (European Perspective), in Zaheer-Ud-Din Babar (ed.). *Equitable Access to High-Cost Pharmaceuticals*, Springer, London: 35-49
- Toumi M, Zard J, Abdallah IB, **Jommi C**, Cohen J (2017). An overview of Market Access Agreements, in Ethgen O, Staginnus O (ed), *The future of Health Economics*. Routledge: 75-108
- **Jommi C**, (2016). An Introduction to Economic Evaluation of Health Care Programs, in Zaheer-Ud-Din Babar (ed.), *Economic evaluation of pharmacy services*, Academic Press, London: 1-9
- **Jommi C**, Minghetti P (2015). Pharmaceutical Pricing Policies in Italy, in Zaheer-Ud-Din Babar (ed.), *Pharmaceutical Prices in the 21st Century*, Springer, London: 131-151
- **Jommi C**, Di Procolo P, Drago V (2013). Education and research on drug market access in low-income countries: the experience of the Department of Pharmaceutical Sciences in Novara, in Missoni E, Tediosi F (ed), *Education in Global Health Policy and Management*, Egea, Milano: 129-151
- **Jommi C**, Aguzzi G, Otto M (2008). Il confronto internazionale tra prezzi dei farmaci: aspetti
- **Jommi C**. (2001), *Pharmaceutical policy and organisation of the regulatory authorities in the main EU countries*, EGEA, Milano.